All Pharma articles
See all articles with this subject.
-
Expert BriefingFollowing the Money: How cash is a ‘growing safety issue’
HSJ’s expert briefing on NHS finances, savings, and efforts to get back in the black. By senior correspondent Zoe Tidman.
-
NewsTrial targets missed despite ‘hit’ claim
The government is missing two of its five clinical trials targets, despite declaring last month it had “hit” its headline goal on trial set-up.
-
CommentThe NHS should be wary about handing the pharma industry its credit card
The US-UK medicines deal will raise NHS drug costs by billions, forcing difficult choices over which services lose funding without additional government investment
-
CommentThe NHS is not ready for the revolution in dementia care
Dementia care could follow cancer’s path of transformation, but only if the NHS addresses longstanding weaknesses in diagnosis, workforce capacity, data and local delivery
-
NewsCandidates for £342k DHSC job to face mock PAC
Candidates for a readvertised post in the Department of Health and Social Care’s executive team, with pay up to £342,000, have been advised to expect a mock public accounts committee grilling.
-
NewsEx-NHSE strategy director joins major PR firm
Former NHS England executive board member Chris Hopson has been appointed to a senior advisory role at a major communications consultancy.
-
HSJ PartnersDemystifying NHS-pharmaceutical industry collaboration: Unlocking value already within reach
This non-promotional article has been fully funded and written by Novartis Pharmaceuticals UK Limited. It is intended for healthcare professionals, other relevant decision makers and patient organisations. Please do not forward, share or post this content beyond the intended audience, including on publicly accessible websites or ...
-
HSJ PartnersUnderstanding the impact of severe asthma to improve patient outcomes
As medical head, specialty at GSK, my work keeps me close to both the lived reality of severe asthma and the system pressures it creates.
-
NewsEx-NHSE director joins NICE top team
The National Institute for Health and Care Excellence has appointed a GP, and former NHS England national clinical director, as its new chief medical officer.
-
HSJ PartnersWorking in partnership to achieve hepatitis C elimination
An unprecedented partnership approach with Gilead Sciences has helped put the UK on track to be one of the first countries to eliminate hepatitis C
-
HSJ PartnersBeyond the minimum: Broadening the field of vision for neighbourhood health
The NHS has been clear about what it wants neighbourhood health to deliver. To succeed, it must be built on the deliberate use of the full breadth of primary care and community partners.
-
CommentBoth government and trusts are to blame for failing MND patients
The programme designed to give early access to an innovative new drug for motor neurone disease is not operating properly
-
Comment‘Cheapest is best’ is still dominating NHS procurement
When buying things, the NHS has focused too much on lowest price, rather than best value. Ministers must not miss the opportunity to put this right
-
NewsFridge door left ajar cost trust £25k
An acute trust was forced to write off £25,000 worth of medication after a pharmacy fridge door was accidentally left ajar.
-
NewsHospitals must update 100,000 pacemakers after safety fault
Hospitals are having to update more than 100,000 patients’ pacemakers – and replace hundreds of the devices – after the manufacturer discovered their batteries run down years early, HSJ has learned.
-
News£340k remuneration deal fails to attract DHSC growth director
The Department of Health and Social Care has failed to find a substantive director general for commercial and growth, despite offering potentially the largest pay packet in the DHSC.
-
CommentWhen safety does not sell
Despite decades of inquiries and warnings, the NHS continues to tolerate predictable medication harm, revealing a system better at analysing failure than preventing it
-
NewsExclusive: DHSC appoints interim commercial chief
The Department of Health and Social Care has appointed an interim director general to run its commercial and growth directorate until July.
-
HSJ PartnersWhat can ctDNA tell us about a patient’s cancer?
Circulating tumour DNA (ctDNA) is transforming how we diagnose and treat complex cancers, particularly when clinical pathways are constrained by the speed, safety, and limitations of tissue biopsy.
-
CommentWhy pharmacy is still excluded from neighbourhood care
Community pharmacy is one of the NHS’s most accessible assets, yet it remains largely excluded from new integrated care models.